- Home
- CUBI vs NVCR Comparison
CUBI vs NVCR Comparison
Compare CUBI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- NVCR
- Stock Information
- Founded
- CUBI 1994
- NVCR 2000
- Country
- CUBI United States
- NVCR Switzerland
- Employees
- CUBI N/A
- NVCR N/A
- Industry
- CUBI Major Banks
- NVCR Medical/Dental Instruments
- Sector
- CUBI Finance
- NVCR Health Care
- Exchange
- CUBI Nasdaq
- NVCR Nasdaq
- Market Cap
- CUBI 1.7B
- NVCR 1.9B
- IPO Year
- CUBI 2012
- NVCR 2015
- Fundamental
- Price
- CUBI $59.54
- NVCR $18.02
- Analyst Decision
- CUBI Buy
- NVCR Buy
- Analyst Count
- CUBI 10
- NVCR 6
- Target Price
- CUBI $65.67
- NVCR $32.83
- AVG Volume (30 Days)
- CUBI 256.4K
- NVCR 1.8M
- Earning Date
- CUBI 07-24-2025
- NVCR 07-24-2025
- Dividend Yield
- CUBI N/A
- NVCR N/A
- EPS Growth
- CUBI N/A
- NVCR N/A
- EPS
- CUBI 3.98
- NVCR N/A
- Revenue
- CUBI $591,500,000.00
- NVCR $621,711,000.00
- Revenue This Year
- CUBI $12.34
- NVCR $5.56
- Revenue Next Year
- CUBI $10.08
- NVCR $9.19
- P/E Ratio
- CUBI $14.81
- NVCR N/A
- Revenue Growth
- CUBI N/A
- NVCR 18.27
- 52 Week Low
- CUBI $40.75
- NVCR $14.17
- 52 Week High
- CUBI $68.49
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CUBI 74.03
- NVCR 47.07
- Support Level
- CUBI $51.61
- NVCR $16.19
- Resistance Level
- CUBI $51.55
- NVCR $18.02
- Average True Range (ATR)
- CUBI 1.41
- NVCR 0.88
- MACD
- CUBI 0.68
- NVCR -0.04
- Stochastic Oscillator
- CUBI 98.16
- NVCR 29.74
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.